Status:
TERMINATED
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
Lead Sponsor:
French Innovative Leukemia Organisation
Conditions:
Lymphoma
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving drugs in different combinations m...
Detailed Description
OBJECTIVES: Primary * Evaluate event-free survival. Secondary * Evaluate overall survival. * Evaluate the prognostic value of FDG-PET scanning. * Evaluate progression-free survival. * Evaluate tol...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA
- Life expectancy \> 3 months
- LVEF normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Must be able to undergo follow-up for ≥ 15 years
- No impaired cardiac function that would preclude the administration of an anthracycline
- No other prior or concurrent malignancy, except for carcinoma in situ of the cervix or basal cell skin cancer
- No respiratory, kidney, or liver failure or other severe clinical insufficiency that would preclude study treatment
- No HIV or hepatitis B virus positivity
- No other disease that would preclude treatment with chemotherapy or radiotherapy
- EXCLUSION CRITERIA:
- No concurrent participation in another experimental trial
Exclusion
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
442 Patients enrolled
Trial Details
Trial ID
NCT00920153
Start Date
May 1 2008
End Date
March 1 2016
Last Update
September 16 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
FILO French Innovative Leukemia Organization
Tours, France, 37044